{"mainPropery":{"diseaseId":7355,"diseaseName":"Pemphigus vulgaris","hasGardWebPage":true,"isRare":true,"websiteUrl":"https://rarediseases.info.nih.gov/diseases/7355/pemphigus-vulgaris","synonyms":[],"synonyms-with-source":[],"identifiers":[{"identifierType":"OMIM","identifierId":"169615"},{"identifierType":"ORPHANET","identifierId":"704"},{"identifierType":"UMLS","identifierId":"C0030809"}]},"diseaseCategories":[{"diseaseTypeId":22,"diseaseTypeName":"Skin Diseases"}],"organizations":[{"resourceID":332,"resourceName":"International Pemphigus & Pemphigoid Foundation","abbreviation":"","address1":"1331 Garden Highway, Suite 100","address2":"","address3":"","address4":"","address5":"","city":"Sacramento","state":"CA","zip":"95833","country":"United States","phone":"916-922-1298 ","tty":"","tollFree":"855-473-6744","fax":"916-922-1458 ","email":"info@pemphigus.org","url":"http://www.pemphigus.org"}],"resource descriptions":[{"id":7,"resourceId":10,"resourceName":"Online Mendelian Inheritance in Man (OMIM)","descriptionText":"<a href='http://www.omim.org/169615' target='_blank'>Online Mendelian Inheritance in Man (OMIM)</a> is a catalog of human genes and genetic disorders. Each entry has a summary of related medical articles. It is meant for health care professionals and researchers. OMIM is maintained by Johns Hopkins University School of Medicine.&nbsp;<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":8,"resourceId":11,"resourceName":"PubMed","descriptionText":"<a href='https://www.ncbi.nlm.nih.gov/pubmed/?term=Pemphigus+vulgaris' target='_blank'>PubMed</a> is a searchable database of medical literature and lists journal articles that discuss Pemphigus vulgaris. Click on the link to view a sample search on this topic.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":9,"resourceId":12,"resourceName":"ClinicalTrials.gov","descriptionText":"<a href='http://www.clinicaltrials.gov/ct2/results?cond=%22Pemphigus+vulgaris%22' target='_blank'>ClinicalTrials.gov</a> lists trials that are related to Pemphigus vulgaris. Click on the link to go to ClinicalTrials.gov to read descriptions of these studies. <br />\r\n<br />\r\n<em><strong>Please note:</strong>&nbsp;Studies listed on the&nbsp;ClinicalTrials.gov&nbsp;website are listed for informational purposes only; being listed does not reflect an endorsement by GARD or the NIH. We strongly recommend that you talk with a trusted healthcare provider before choosing to participate in any clinical study.</em>","resourceClassificationName":"Research","resourceClassificationSectionName":"Clinical Research Resources"},{"id":336,"resourceId":1154,"resourceName":"RareConnect","descriptionText":"<div style=\"margin-top: 0px; margin-bottom: 0px;\"><a href='https://www.rareconnect.org/en/community/pemphigus-and-pemphigoid' target='_blank'>RareConnect</a> has an online community for patients&nbsp;and families with this condition so they can connect with others and share&nbsp;their experiences living with a rare disease.&nbsp;The project is a joint collaboration between EURORDIS (European Rare Disease Organisation) and NORD (National Organization for Rare Disorders).</div>","resourceClassificationName":"Organizations","resourceClassificationSectionName":"Social Networking Websites"},{"id":1457,"resourceId":2104,"resourceName":"Genetic Services","descriptionText":"To find a medical professional who specializes in genetics, you can ask your doctor for a referral or you can search for one yourself. Online directories are provided by the <a href='http://www.acmg.net/ACMG/Genetic_Services_Directory_Search.aspx' target='_blank'>American College of Medical Genetics</a> and the&nbsp;<a href='https://www.findageneticcounselor.com/' target='_blank'>National Society of Genetic Counselors</a>. If you need additional help, <a href=\"https://rarediseases.info.nih.gov/about-gard/contact-gard\">contact a GARD Information Specialist</a>. You can also&nbsp;<a href='https://ghr.nlm.nih.gov/primer#consult' target='_blank'>learn more about genetic consultations</a>&nbsp;from Genetics Home Reference.","resourceClassificationName":"Find a Specialist","resourceClassificationSectionName":"Healthcare Resources"},{"id":1527,"resourceId":2159,"resourceName":"National Organization for Rare Disorders","descriptionText":"The <a href='http://www.rarediseases.org/rare-disease-information/rare-diseases/byID/44/viewAbstract' target='_blank'>National Organization for Rare Disorders</a> (NORD) has a report for patients and families about this condition. NORD is a patient advocacy organization for individuals with rare diseases and the organizations that serve them.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1529,"resourceId":2128,"resourceName":"MedlinePlus","descriptionText":"<a href='http://www.nlm.nih.gov/medlineplus/ency/article/000882.htm' target='_blank'>MedlinePlus</a> was designed by the National Library of Medicine to help you research your health questions, and it provides more information about this topic.\r\n<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1531,"resourceId":2162,"resourceName":"Medscape Reference","descriptionText":"<a href='http://emedicine.medscape.com/article/1064187-overview' target='_blank'>Medscape Reference</a> provides information on this topic. You may need to register to view the medical textbook, but registration is free.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":1534,"resourceId":2165,"resourceName":"Orphanet","descriptionText":"<a href='http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=704' target='_blank'>Orphanet</a> is a European reference portal for&nbsp;information on rare diseases and orphan drugs. Access to this database is free of charge.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":1562,"resourceId":2179,"resourceName":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","descriptionText":"The <a href='http://www.niams.nih.gov/Health_Info/Pemphigus/default.asp' target='_blank'>National Institute of Arthritis and Musculoskeletal and Skin Diseases</a> (NIAMS) support research into the causes, treatment, and prevention of arthritis and musculoskeletal and skin diseases, the training of basic and clinical scientists to carry out this research, and the dissemination of information on research progress in these diseases.  Click on the link to view information onÂ this topic.","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":2135,"resourceId":3342,"resourceName":"Monarch Initiative","descriptionText":"The <a href='https://monarchinitiative.org/disease/OMIM:169610' target='_blank'>Monarch Initiative</a> brings together data about this condition from humans and other species to help physicians and biomedical researchers. Monarch&rsquo;s tools are designed to make it easier to compare the signs and symptoms (phenotypes) of different diseases and discover common features. This initiative is a collaboration between several academic institutions across the world and is funded by the National Institutes of Health. Visit the website to explore the biology of this condition.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":2722,"resourceId":4053,"resourceName":"Patient Registry","descriptionText":"A registry supports research by collecting of information about patients that share something in common, such as being diagnosed with Pemphigus vulgaris. The type of data collected can vary from registry to registry and is based on the goals and purpose of that registry. Some registries collect contact information while others collect more detailed medical information. <a href=\"https://www.nih.gov/health-information/nih-clinical-research-trials-you/list-registries\" target=\"_blank\">Learn more about registries</a>.<br />\r\n<br />\r\nRegistries for&nbsp;Pemphigus vulgaris:<br />\r\n<a href='http://www.pemphigus.org/research/pemphigus-pemphigoid-registry/' target='_blank'>International Pemphigus & Pemphigoid Foundation Natural History Registry</a><br />&nbsp;","resourceClassificationName":"Research","resourceClassificationSectionName":"Patient Registry"},{"id":2781,"resourceId":4265,"resourceName":"Autoimmune Registry","descriptionText":"The <a href='http://www.autoimmuneregistry.org/' target='_blank'>Autoimmune Registry</a> supports research for Pemphigus vulgaris by collecting information about patients with this and other autoimmune diseases. You can join the registry to share your information with researchers and receive updates about participating in new research studies.&nbsp;<a href=\"https://www.nih.gov/health-information/nih-clinical-research-trials-you/list-registries\" target=\"_blank\">Learn more about registries.</a>","resourceClassificationName":"Research","resourceClassificationSectionName":"Patient Registry"}],"overviewQuestion":{"questionId":3158,"questionText":"What is pemphigus vulgaris?","answerText":"<strong>Pemphigus vulgaris</strong> is an <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/000816.htm\" target=\"_blank\">autoimmune disorder</a> that involves blistering and erosion of the skin and <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/002264.htm\" target=\"_blank\">mucous membranes</a>. It occurs almost exclusively in middle-aged or older people. The primary lesion of pemphigus vulgaris is a soft blister filled with clear fluid that appears on healthy or irritated skin.&nbsp;Many cases begin with blisters in the mouth, followed by skin blisters that&nbsp;may come and go. The blisters inside the mouth can make it hard for the person to eat. The rupture of blisters on the skin may be painful and limit the person's daily activities.[2152][2153][10256] Complications due to infections can be serious and the damaging nature of the blisters can cause loss of body fluids and protein.[14745] The exact cause of pemphigus vulgaris is unknown, but the blisters in pemphigus vulgaris are associated with the binding of&nbsp;<a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/002223.htm\" target=\"_blank\">antibodies</a>&nbsp;to the skin cells.[2152][2153][10256][14745] Treatment is aimed at reducing symptoms and preventing complications, and may include the use of <a href=\"http://www.nlm.nih.gov/medlineplus/steroids.html\" target=\"_blank\">corticosteroids</a>, <a href=\"https://www.kidney.org/atoz/content/immuno\" target=\"_blank\">i</a><a href=\"https://www.kidney.org/atoz/content/immuno\" target=\"_blank\">mmunosuppressive drugs</a>, and more recently <a href=\"https://medlineplus.gov/ency/patientinstructions/000903.htm\" target=\"_blank\">immunotherapy</a>. Pemphigus vulgaris may require long term treatment to keep it in remission.[2152][10256][14745]","dateModified":"2018-06-22T00:00:00"},"basicQuestions":[{"questionId":3159,"questionText":"What causes pemphigus vulgaris?","answerText":"Pemphigus vulgaris is an&nbsp;<a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/000816.htm\" target=\"_blank\">autoimmune disorder</a>. In the case of pemphigus vulgaris, the immune system mistakenly produces <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/002223.htm\" target=\"_blank\">antibodies</a> against specific proteins in the skin and mucous membranes, known as desmogleins. These proteins form the glue that keeps skin cells attached and the skin intact. When desmogleins are attacked, skin cells separate from each other and fluid can collect between the layers of skin, forming blisters that do not heal. In some cases, these blisters can cover a large area of skin.[2152][2155]<br />\r\n<br />\r\n<span>Although it is rare, some cases of pemphigus vulgaris are&nbsp;caused by <a href=\"http://emedicine.medscape.com/article/1063684-overview\" target=\"_blank\">certain medications</a>. Among others, medications that may cause this condition include:[2152][10256]</span>\r\n<ul>\r\n    <li>Blood pressure medications called <a href=\"http://www.nlm.nih.gov/medlineplus/ency/patientinstructions/000087.htm\" target=\"_blank\">ACE inhibitors</a>&nbsp;such as captopril</li>\r\n    <li>Chelating agents such as <a href=\"http://www.mayoclinic.com/health/drug-information/DR601085\" target=\"_blank\">penicillamine</a>, which remove certain materials from the blood</li>\r\n    <li>Antibiotics such as cephalosporin</li>\r\n    <li>Pyrazolones</li>\r\n    <li><a href=\"https://www.rheumatology.org/I-Am-A/Patient-Caregiver/Treatments/NSAIDs\" target=\"_blank\">N<span>onsteroidal anti-inflammatory drugs (NSAIDs)</span></a></li>\r\n    <li><span><a href=\"https://medlineplus.gov/druginfo/meds/a682403.html\" target=\"_blank\">Rifampin</a></span></li>\r\n</ul>\r\n<p>Emotional stress, thermal burns, ultraviolet rays, and infections have also been reported as triggers for pemphigus vulgaris.<br />\r\n<br />\r\nWhile in many cases the exact cause of pemphigus vulgaris remains unknown, several potentially relevant factors have been identified.[2153][10256]</p>\r\n<ul>\r\n    <li><span style=\"text-decoration: underline;\">Genetic Factors</span>: Predisposition to pemphigus is linked to genetic factors.<sup> </sup>Certain major histocompatibility complex (MHC) class II molecules, in particular alleles of human leukocyte antigen (HLA) DR4, appear to increase susceptibility to pemphigus vulgaris.<sup> </sup>\r\n    </li>\r\n    <li><span style=\"text-decoration: underline;\">Age</span>: Peak age of onset is from 50-60 years. Infants with neonatal pemphigus typically recover after protection from their mother's antibodies have cleared their systems. The disease may, nonetheless,&nbsp;develop at any age.\r\n    </li>\r\n    <li><span style=\"text-decoration: underline;\">Disease Association</span>: Pemphigus occurs more commonly in people who&nbsp;also have other autoimmune diseases, particularly&nbsp;<a href=\"http://emedicine.medscape.com/article/1171206-overview\" target=\"_blank\">myasthenia gravis</a> and&nbsp;<a href=\"http://emedicine.medscape.com/article/193809-overview\" target=\"_blank\">thymoma</a>.</li>\r\n</ul>\r\n<p>Pemphigus is not contagious. It does not spread from person to person. Though there can be a genetic predisposition to develop pemphigus, there is no indication the disease is hereditary.[2155]</p>","dateModified":"2018-06-22T00:00:00","resourceClassificationName":"Cause","references":[{"referenceId":2152,"authors":"Berman K","articleTitle":"Pemphigus vulgaris","bookWebsiteJournalTitle":"MedlinePlus","date":"April 29, 2016","volume":"","pages":"","url":"https://medlineplus.gov/ency/article/000882.htm","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":2153,"authors":"","articleTitle":"Pemphigus Vulgaris, Familial","bookWebsiteJournalTitle":"Online Mendelian Inheritance in Man (OMIM)","date":"2012","volume":"","pages":"","url":"http://omim.org/entry/169610","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":2155,"authors":"","articleTitle":"Pemphigus","bookWebsiteJournalTitle":"National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)","date":"2015","volume":"","pages":"","url":"http://www.niams.nih.gov/Health_Info/Pemphigus/default.asp","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":10256,"authors":"Zeina B","articleTitle":"Pemphigus Vulgaris","bookWebsiteJournalTitle":"Medscape Reference","date":"June 14, 2018","volume":"","pages":"","url":"http://emedicine.medscape.com/article/1064187-overview","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":11252,"questionText":"How might pemphigus vulgaris be treated?","answerText":"<span>The goal of treatment of pemphigus vulgaris is to promote and maintain remission, as well as avoid complications, such as infections. Medications and therapies are used to decrease blister formation and promote healing of blisters and reduce scarring. Once in remission, it is important to determine the minimal dose of medication necessary to control the disease process, since both long term use of steroids and other&nbsp; immunosuppressive drugs can increase the risk of other medical problems. Treatment is individualized, and takes into account the person's other health conditions.[2152][10256][14745]&nbsp;&nbsp;</span><br />\r\n<br />\r\n<span>The most common first line therapy for pemphigus vulgaris is:[10256][14745]&nbsp;</span><br />\r\n<ul>\r\n    <li><span>Steroids (<a href=\"https://medlineplus.gov/steroids.html\" target=\"_blank\">corticosteroids</a>), such as <a href=\"https://medlineplus.gov/druginfo/meds/a601102.html\" target=\"_blank\">prednisone</a>. Steroids can help a person go into remission and stay in remission, however this must be balanced with the medical problems that can be caused by the long term use of steroids.</span></li>\r\n</ul>\r\nOther immunosuppessives and immunotherapies may be used in addition to steroid therapy to reduce the risk of relapse or to reduce the dosage strength of the steroid being used. Again the choice of the additional drug or therapy (adjuvant therapy) must be balanced against the possible negative side effects.<br />\r\n<br />\r\nMost common choices to be added to steroid treatment (first line adjuvant therapies) include:[10256][14745]<br />\r\n<ul>\r\n    <li><span><a href=\"https://medlineplus.gov/druginfo/meds/a607038.html\" target=\"_blank\">Rituximab</a>&nbsp;(received FDA approval for PV in June 2018)</span></li>\r\n    <li><span><a href=\"https://medlineplus.gov/druginfo/meds/a682167.html\" target=\"_blank\">Azathioprine</a></span></li>\r\n    <li><span><a href=\"https://medlineplus.gov/druginfo/meds/a601081.html\" target=\"_blank\">Mycophenolate mofetil</a> (MMF)</span></li>\r\n</ul>\r\n<span>Other choices may include:[10256][14745]&nbsp;</span>\r\n<ul>\r\n    <li><a href=\"http://primaryimmune.org/treatment-information/immunoglobulin-therapy/\" style=\"font-size: 12pt;\">Intravenous immunoglobulin therapy</a><span style=\"font-size: 12pt;\">&nbsp;(IVIg)</span></li>\r\n    <li><span style=\"font-size: 12pt;\"><a href=\"https://medlineplus.gov/druginfo/meds/a682080.html\" target=\"_blank\">Cyclophosphamide</a>, <a href=\"https://medlineplus.gov/druginfo/meds/a682019.html\" target=\"_blank\">methotrexate</a>, or&nbsp;<a href=\"https://medlineplus.gov/druginfo/meds/a682128.html\">dapsone</a>,</span></li>\r\n    <li><span style=\"font-size: 12pt;\">Immunoadsorption (blood purification procedure that removes disease causing antibodies)</span></li>\r\n</ul>\r\nAdditional medications may be considered if a person does not achieve remission with a combination of steroids and one of the medications or therapies listed above.[10256] <br />\r\n<br />\r\nAntibiotics, antivirals, and antifungals may be used to prevent or fight an infection.&nbsp;Wound care may include baths and wound dressings to help heal blisters and sores. Severe cases of pemphigus vulgaris may require hospital stays to receive proper wound care, as well as intravenous fluids and electrolytes if mouth ulcers are severe. Treatment may also involve pain medication or pain management therapies.[2152]","dateModified":"2018-06-22T00:00:00","resourceClassificationName":"Treatment","references":[{"referenceId":2152,"authors":"Berman K","articleTitle":"Pemphigus vulgaris","bookWebsiteJournalTitle":"MedlinePlus","date":"April 29, 2016","volume":"","pages":"","url":"https://medlineplus.gov/ency/article/000882.htm","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":10256,"authors":"Zeina B","articleTitle":"Pemphigus Vulgaris","bookWebsiteJournalTitle":"Medscape Reference","date":"June 14, 2018","volume":"","pages":"","url":"http://emedicine.medscape.com/article/1064187-overview","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":14745,"authors":"Kridin K","articleTitle":"Emerging treatment options for the management of pemphigus vulgaris","bookWebsiteJournalTitle":"Therapeutics and Clinical Risk Management","date":"April 27, 2018","volume":"14","pages":"757-778","url":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5931200/","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":3161,"questionText":"What is the prognosis for individuals with&nbsp;pemphigus vulgaris?","answerText":"Recent advances in the treatment of pemphigus vulgaris have significantly improved the long term outlook for people with the disease.<span> For most people, the disease can be controlled with prednisone (corticosteroids) in combination with other medications or therapies. However, both the use of steroids and the other medications or therapies can cause side effects that may sometimes be serious, including increasing the risk of developing a fatal infection. Pemphigus vulgaris and its treatments can be debilitating and may cause lost time at work, weight loss, loss of sleep, and emotional distress. Connecting with others facing the same concerns and challenges can help a person cope with  the changes the disease causes in their life.[2152][2155][14745]</span><br />\r\n<br />\r\nThe&nbsp;<a href=\"http://www.pemphigus.org/\" target=\"_blank\">International Pemphigus Foundation</a>&nbsp;provides patient support services to help people with the disease cope with its effects.[2155]","dateModified":"2018-06-22T00:00:00","resourceClassificationName":"Prognosis","references":[{"referenceId":2152,"authors":"Berman K","articleTitle":"Pemphigus vulgaris","bookWebsiteJournalTitle":"MedlinePlus","date":"April 29, 2016","volume":"","pages":"","url":"https://medlineplus.gov/ency/article/000882.htm","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":2155,"authors":"","articleTitle":"Pemphigus","bookWebsiteJournalTitle":"National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)","date":"2015","volume":"","pages":"","url":"http://www.niams.nih.gov/Health_Info/Pemphigus/default.asp","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":14745,"authors":"Kridin K","articleTitle":"Emerging treatment options for the management of pemphigus vulgaris","bookWebsiteJournalTitle":"Therapeutics and Clinical Risk Management","date":"April 27, 2018","volume":"14","pages":"757-778","url":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5931200/","authors2":"","placeOfPublication":"","publisher":""}]}],"references":[],"relatedDiseases":[],"gardCases":[],"news":[{"newsId":671,"dateCreated":"2020-05-20T13:39:00","publishDate":"2020-05-22T00:00:00","title":"NIH-Supported Research Survey to Examine Impact of COVID-19 on Rare Diseases Community","description":"The NIH-funded Rare Diseases Clinical Research Network (RDCRN) has launched an <a href=\"https://www.rarediseasesnetwork.org/COVIDsurvey \" target=\"_blank\">online research survey</a> to find out how the COVID-19 pandemic is impacting individuals with rare diseases, their families and their caregivers. Your participation can help the rare disease research community shed light on the needs of people with rare diseases during this and other potential health crises, in addition to informing future research efforts. The survey must be completed by December 15, 2020.","url":"https://www.rarediseasesnetwork.org/COVIDsurvey","lastModified":"2020-11-30T14:44:00","isFeatured":false}],"conferences":[],"phenoTypes":[{"phenoTypeId":1325,"phenoTypeName":"Abnormal blistering of the skin","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":9763,"phenoTypeName":"Abnormal oral cavity morphology","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":1861,"phenoTypeName":"Acantholysis","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":8269,"phenoTypeName":"Atypical scarring of skin","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":4355,"phenoTypeName":"Autoimmunity","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":3410,"phenoTypeName":"Feeding difficulties in infancy","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":11850,"phenoTypeName":"Recurrent cutaneous abscess formation","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":8303,"phenoTypeName":"Urticaria","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":5059,"phenoTypeName":"Weight loss","frequencyText":"Very frequent","percentRanges":"80%-99%"}],"medicalProducts":[{"productId":725,"genericName":"Rituximab","tradeName":"Rituxan","tradeLink":"https://www.rituxanforpv.com/","manufacturer":"","sponsor":"Genentech, Inc.","indication":"June 2018, approved for the treatment of adult patients with moderate to severe pemphigus vulgaris.","drugInformationLink":"https://druginfo.nlm.nih.gov/drugportal/name/rituxan","medlinePlusLink":"https://medlineplus.gov/druginfo/meds/a607038.html"}],"EncodedName":"Pemphigus_vulgaris"}